Posted by JohnB on November 17, 2000, at 23:00:26
In reply to Reboxetine and Wellbutrin, posted by 993 on November 16, 2000, at 11:31:30
> Anyone have any ideas or experience with this combo?
Hi 993,
I've taken WB since February and am currently doing a trial of Rebox augmentation (starting at 2mg/day). I am doing so based on my feeling that I have a noradrenic deficiency, (fatigue, apathy, problems with concentration, focus, slow info processing, memory, etc). WB has some noradrenic action, and Rebox is an NRI (selective norepinephrine reuptake inhibitor), so this is a good way to get a lot of noradrenic action.
If you have symtoms like the above, Rebox + WB could be helpful. If your symptoms are different, Rebox will probably cause too much agitation. For instance, someone with panic attacks or a lot of anxiety, phobias, etc., should not add Rebox to WB.
My personal experience about Rebox: I give it a cautious thumbs up at the 2 week mark. It does seem to improve energy. Side effects: Muscle tightness/twitching, may feel too wide-awake (take it in the morning), sexual numbing. The literature I've read suggest these may diminish over time.
My hopes are not high for this drug. Many people on this board have tried Rebox, but have given it up for various reasons. Do a search of previous posts all the way back into 1999 for more info/personal experiences. --JB_______________________________________________________________________
Int Clin Psychopharmacol 2000 Sep;15(5):279-89
The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, Williamson T
Analysis Group/Economics, Cambridge, MA 02138, USA.
[Medline record in process]
Depression compromises affected individuals' functional well-being and impairs their level of social and workplace performance. Improved social functioning in depressed patients may improve their work productivity. This study evaluated the differential effects of two antidepressants on social functioning outcomes for patients with major depression comparing reboxetine, a non-tricyclic, selective noradrenaline reuptake inhibitor and fluoxetine, a commonly prescribed selective serotonin reuptake inhibitor. A model using data from 284 depressed patients (138 reboxetine, 146 fluoxetine) in two 8-week clinical trials was developed to predict the percentage change over time in continuous outcome assessments as measured by a 21-item self-rating scale called the Social Adaptation Self-evaluation Scale (SASS). The percentage change from baseline SASS score was modelled as a function of both time-invariant and time-varying covariates. Results suggest that, by mid-study, the more severely ill subjects benefitted more from reboxetine treatment in terms of the outcome improvement rate and, by study-end, this effect also extended into the less severely ill population. In addition, a significant relationship was identified between the change in depression symptom severity as measured by the standard Hamilton Depression Rating Scale score and the change in social functioning per the SASS.
PMID: 10993130, UI: 20445226
poster:JohnB
thread:48906
URL: http://www.dr-bob.org/babble/20001115/msgs/49002.html